Methonac Tablet contains Acetylcysteine 600 mg, a mucolytic agent primarily used to reduce the viscosity of mucus in respiratory conditions characterized by excessive or thickened secretions. Acetylcysteine acts by breaking disulfide bonds in mucoproteins, thereby liquefying bronchial secretions and facilitating their expectoration. This medication is indicated in the management of chronic obstructive pulmonary disease (COPD), bronchitis, cystic fibrosis, and other respiratory disorders where mucus clearance is impaired. Additionally, Methonac is utilized as an antidote in acetaminophen (paracetamol) overdose to prevent hepatic injury by replenishing intracellular glutathione stores, thereby enhancing detoxification of the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). The recommended dosage and duration of therapy should be determined by a healthcare professional based on the specific indication and patient condition. Methonac Tablet is generally well tolerated; however, some patients may experience adverse effects such as gastrointestinal disturbances, rash, or rarely bronchospasm. Caution is advised in individuals with asthma or hypersensitivity to acetylcysteine. Methonac should be used under medical supervision, and patients are advised to report any unusual symptoms promptly. This formulation provides an effective therapeutic option for managing mucus-related respiratory conditions and acetaminophen toxicity.